Literature DB >> 15914323

Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis.

Yong-Wook Shin1, Eun-Ah Bae, Sung-Soo Kim, Young-Chul Lee, Dong-Hyun Kim.   

Abstract

During the screening program to discover antipsoriatic agents from natural products, ginseng was found to show inhibitory activity in oxazolone-induced mouse ear dermatitis. Therefore, the effects of a main constituent ginsenoside Rb1 isolated from ginseng and its metabolite compound K on oxazolone-induced mouse ear dermatitis were investigated. Compound K at concentrations of 0.02% and 0.05% also potently suppressed mouse ear swelling by 54% and 76% at 16 days, respectively, although ginsenoside Rb1 did not significantly show the inhibitory activity. The compound K also significantly reduced the levels of mRNA of cyclooxygenase (COX)-2, IL-1beta, TNF-alpha, IFN-gamma and IL-4 increased in oxazolone-applied mouse ears. Based on these findings, the compound K may improve contact dermatitis or psoriasis by the regulation of COX-2 produced by macrophage cells and interferon-gamma and IL-4 induced by Th cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914323     DOI: 10.1016/j.intimp.2005.02.016

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  17 in total

1.  Effects of ginsenoside Rg2 on the ultraviolet B-induced DNA damage responses in HaCaT cells.

Authors:  Se Eun Ha; Dae Hyun Shin; Hyung Do Kim; Sun Mi Shim; Hack Soo Kim; Bo Hyeon Kim; Jung Sup Lee; Jong Kun Park
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-05-28       Impact factor: 3.000

2.  Kakkalide and its metabolite irisolidone ameliorate carrageenan-induced inflammation in mice by inhibiting NF-κB pathway.

Authors:  Sung-Won Min; Young-Jun Park; Dong-Hyun Kim
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

3.  Kalopanaxsaponin A ameliorates experimental colitis in mice by inhibiting IRAK-1 activation in the NF-κB and MAPK pathways.

Authors:  Eun-Ha Joh; Dong-Hyun Kim
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 4.  Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides.

Authors:  Huai-You Wang; Lian-Wen Qi; Chong-Zhi Wang; Ping Li
Journal:  Am J Chin Med       Date:  2011       Impact factor: 4.667

Review 5.  Chinese medicines reported to have effects on contact dermatitis in the last 20 years.

Authors:  Youngchul Jung; Byungju Kim; Mi Heon Ryu; Hyungwoo Kim
Journal:  Chin J Integr Med       Date:  2017-03-02       Impact factor: 1.978

6.  Lancemaside A ameliorates colitis by inhibiting NF-kappaB activation in TNBS-induced colitis mice.

Authors:  Eun-Ha Joh; In-Ah Lee; Sang-Jun Han; Sunju Chae; Dong-Hyun Kim
Journal:  Int J Colorectal Dis       Date:  2009-12-03       Impact factor: 2.571

7.  Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis.

Authors:  Jung-Hee Lee; Bomi Lee; Hye-Sung Lee; Eun-Ah Bae; Hoyong Lee; Young-Tae Ahn; Kwang-Sei Lim; Chul-Sung Huh; Dong-Hyun Kim
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

8.  Ginsenoside compound K suppresses the abnormal activation of T lymphocytes in mice with collagen-induced arthritis.

Authors:  Kang-kang Liu; Qing-tong Wang; Si-min Yang; Jing-yu Chen; Hua-xun Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2014-04-14       Impact factor: 6.150

9.  The role of intestinal microflora in anti-inflammatory effect of baicalin in mice.

Authors:  Myung-Ah Jung; Se-Eun Jang; Sung-Woon Hong; Myung Joo Hana; Dong-Hyun Kim
Journal:  Biomol Ther (Seoul)       Date:  2012-01       Impact factor: 4.634

10.  Intestinal metabolite compound K of panaxoside inhibits the growth of gastric carcinoma by augmenting apoptosis via Bid-mediated mitochondrial pathway.

Authors:  Chun Hu; Gang Song; Bing Zhang; Zhongchen Liu; Rong Chen; Hong Zhang; Tianhui Hu
Journal:  J Cell Mol Med       Date:  2012-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.